NY-TERRAFORMATION
3.11.2022 08:22:41 CET | Business Wire | Press release
Terraformation, a global reforestation company, has launched the Seed to Carbon Forest Accelerator, the world’s first biodiversity-focused, carbon-funded forest accelerator program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221031005421/en/
Photo: The Kilimanjaro Project (Photo: Business Wire)
In the next decade, the world will need thousands of new reforestation teams to capture carbon at scale and limit the impacts of climate change. The new forest accelerator will help meet this need by providing forestry teams with the tools to launch restoration projects and succeed at scale. These include early-stage financing, training in resilient native ecosystem restoration, and tools to increase project transparency in critical early stages.
This wraparound platform to launch emerging forestry teams is unique in the industry and brings much-needed support to expand the supply of forest carbon.
The carbon buyers and companies who provide early financing to accelerator cohorts lock in access to the premium-quality carbon credits the projects generate. By providing this financing, buyers secure access to a portfolio of verified carbon credits from geographically diverse projects selected by the company’s carbon science team. Terraformation is looking to connect with finance partners to launch a new accelerator cohort early next year.
The accelerator program is a direct response to the largest bottlenecks to mass-scale restoration: in a recent Terraformation survey of 230 forestry organizations around the globe, 95% of respondents said funding was their biggest concern.[1]
The accelerator builds on Terraformation’s successful pilot restoration projects. Since the company began its global programs in 2020, it has successfully launched 16 restoration projects across 11 countries and created more than 400 new sustainable jobs.
Yishan Wong, founder and CEO of Terraformation, said: “The planet needs to rapidly scale reforestation efforts to address the climate crisis. And more investors than ever are looking for opportunities in carbon capture. But there hasn’t been a clear vehicle providing those investors access to high-quality carbon credits. At the same time, communities around the world are launching vital restoration efforts, but lack the funding, training and technology they need to scale.
“Our accelerator will rapidly expand the number of high-quality forest restoration projects and increase the planet’s capacity for carbon capture.”
María José Iturralde, co-founder of Humans for Abundance, a Terraformation restoration partner, said: “Funding can turn land management around by supporting new sustainable business models that replace deforestation for profit. Startup capital creates opportunities for training, education and infrastructure that allows communities to sustainably restore ecosystems and commercialize their new products in a new way.”
Apply to the accelerator
Applying to and participating in the Seed to Carbon Forest Accelerator is free and open to all forestry teams that prioritize biodiversity and benefits to local communities. Interested organizations and forestry teams are invited to apply to the accelerator beforeNovember 27, 2022. Read more and apply here.
Selected teams will receive a feasibility study to assess carbon project viability on their land, as well as access to expert training in seed collection and banking, biodiverse forest restoration, sustainable business models, marketing and finance. Teams will also receive access to carbon buyers, as well as to new, state-of-the-art project tracking software to streamline monitoring, reporting and verification of project progress, and more. Terraformation will encourage forestry teams to promote women’s leadership, offer community education and create sustainable, local economic impact.
Forestry teams selected to participate in the first cohort will be announced in early 2023.
Fund new forest carbon projects
Carbon buyers and companies interested in funding accelerator forest projects and accessing premium-quality, biodiverse, verified carbon credits can learn more here.
*ENDS*
NOTE TO EDITORS:
About Terraformation
Terraformation is dedicated to restoring the world’s forests to stabilize our climate, revive ecosystems, and build thriving communities.
The company hosts a forest carbon accelerator, supporting early-stage forestry teams to launch, build, and scale biodiverse reforestation projects. In addition to producing high-quality, verified carbon credits, these projects generate complementary sustainable revenue streams to support local economies.
Terraformation’s current partner network spans five continents and includes diverse landowners and organizations. It was founded in 2019 by Yishan Wong, former CEO of Reddit.
Footnotes
[1] Terraformation research conducted in summer 2022 with a survey of 230 respondents from 63 countries. Interviews were also completed with 70 respondents from 29 countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005421/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
